DE60031422T2 - Peptidanaloga als selektive Inhibitoren der Thrombinaktivierung des proteaseaktivierten Rezeptors 1 - Google Patents

Peptidanaloga als selektive Inhibitoren der Thrombinaktivierung des proteaseaktivierten Rezeptors 1 Download PDF

Info

Publication number
DE60031422T2
DE60031422T2 DE60031422T DE60031422T DE60031422T2 DE 60031422 T2 DE60031422 T2 DE 60031422T2 DE 60031422 T DE60031422 T DE 60031422T DE 60031422 T DE60031422 T DE 60031422T DE 60031422 T2 DE60031422 T2 DE 60031422T2
Authority
DE
Germany
Prior art keywords
thrombin
formula
seq
amino acid
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60031422T
Other languages
German (de)
English (en)
Other versions
DE60031422D1 (de
Inventor
H. Alvin Ann Arbor SCHMAIER
Ahmed A. K. Scio Township Dexter HASAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thromgen Inc Ann Arbor
University of Michigan System
Thromgen Inc
University of Michigan Ann Arbor
Original Assignee
Thromgen Inc Ann Arbor
University of Michigan System
Thromgen Inc
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thromgen Inc Ann Arbor, University of Michigan System, Thromgen Inc, University of Michigan Ann Arbor filed Critical Thromgen Inc Ann Arbor
Publication of DE60031422D1 publication Critical patent/DE60031422D1/de
Application granted granted Critical
Publication of DE60031422T2 publication Critical patent/DE60031422T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE60031422T 1999-08-17 2000-08-17 Peptidanaloga als selektive Inhibitoren der Thrombinaktivierung des proteaseaktivierten Rezeptors 1 Expired - Fee Related DE60031422T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/375,808 US6544750B1 (en) 1999-08-17 1999-08-17 Peptide analogs as selective inhibitors of thrombin activation of protease activated receptor 1
US375808 1999-08-17
PCT/US2000/040669 WO2001012656A1 (en) 1999-08-17 2000-08-17 Peptide analogs as selective inhibitors of thrombin activation of protease activated receptor 1

Publications (2)

Publication Number Publication Date
DE60031422D1 DE60031422D1 (de) 2006-11-30
DE60031422T2 true DE60031422T2 (de) 2007-08-23

Family

ID=23482441

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60031422T Expired - Fee Related DE60031422T2 (de) 1999-08-17 2000-08-17 Peptidanaloga als selektive Inhibitoren der Thrombinaktivierung des proteaseaktivierten Rezeptors 1

Country Status (9)

Country Link
US (1) US6544750B1 (enExample)
EP (1) EP1212352B1 (enExample)
JP (1) JP2003507389A (enExample)
AT (1) ATE342914T1 (enExample)
AU (1) AU764707B2 (enExample)
CA (1) CA2382056A1 (enExample)
DE (1) DE60031422T2 (enExample)
IL (1) IL148173A0 (enExample)
WO (1) WO2001012656A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US6841354B2 (en) * 2000-12-21 2005-01-11 Philadelphia, Health & Education Corporation Screening assay for anti-thrombotic/anti-platelet activity
JP2005537245A (ja) * 2002-06-26 2005-12-08 エントレメッド インコーポレイテッド タンパク質活性化レセプターのアンタゴニストを含む組成物および方法
US7074765B2 (en) 2003-05-01 2006-07-11 The Regents Of The University Of Michigan Synthetic peptide analogs of Arg-Pro-Pro-Gly-Phe as selective inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4
WO2006023844A2 (en) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
WO2006045503A1 (en) 2004-10-19 2006-05-04 Lonza Ag Method for solid phase peptide synthesis
AU2011336345B2 (en) 2010-12-02 2016-07-07 Becton, Dickinson And Company Blood collection devices containing blood stabilization agent
EP2988130A1 (en) * 2014-08-20 2016-02-24 Eppendorf Ag Method for coating a solid support
US20180214476A1 (en) * 2017-02-01 2018-08-02 North Carolina State University Thrombin-responsive hydrogels and devices for auto-anticoagulant regulation
CN113429459B (zh) * 2021-06-16 2022-07-26 昆明医科大学第一附属医院 一种抗血小板多肽及其药物组合物与其应用
CN116370339A (zh) * 2023-05-24 2023-07-04 南京百沃锐医药研究院有限公司 一种环肽用作抗皮肤光老化活性因子及用于制备抗光老化化妆品的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0410540A1 (en) * 1989-07-28 1991-01-30 Merck & Co. Inc. Fibrinogen receptor antagonists
WO1992007269A1 (en) 1990-10-11 1992-04-30 Pro-Soma S.A.R.L. Diagnostic method
US5461032A (en) * 1991-03-01 1995-10-24 Fmc Corporation Insecticidally effective peptides
IE20030749A1 (en) 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
AU2548992A (en) 1991-08-13 1993-03-16 Temple University - Of The Commonwealth System Of Higher Education Modulation of blood pressure and inhibition of platelet activation with kininogen fragment
US5225531A (en) * 1992-04-09 1993-07-06 Washington University Hexapeptide Lys Gly Ala Gly Asp Val
US5747447A (en) * 1992-04-30 1998-05-05 Cor Therapeutics Stable polypeptide composition
US5589458A (en) 1992-11-13 1996-12-31 Thomas Jefferson University Compounds that inhibit T cell proliferation and methods for using the same
US5631131A (en) 1993-03-19 1997-05-20 Universite De Montreal cDNA probes and antibodies for human methenyltetrahydrofolate synthetase
US5491086A (en) 1993-05-14 1996-02-13 Hoffmann-La Roche Inc. Purified thermostable nucleic acid polymerase and DNA coding sequences from pyrodictium species
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
ATE235912T1 (de) * 1995-06-09 2003-04-15 Univ Michigan Bradikininanaloge als selektive thrombininhibitoren
IL132546A0 (en) 1997-04-23 2001-03-19 Univ Michigan Bradykinin analogs as selective inhibitors of cell activation
AU2662999A (en) 1998-02-09 1999-08-23 Genzyme Corporation Nucleic acid delivery vehicles
US6111075A (en) 1998-04-01 2000-08-29 Zymogenetics, Inc. Protese-activated receptor PAR4 (ZCHEMR2)

Also Published As

Publication number Publication date
IL148173A0 (en) 2002-09-12
JP2003507389A (ja) 2003-02-25
ATE342914T1 (de) 2006-11-15
WO2001012656A1 (en) 2001-02-22
AU764707B2 (en) 2003-08-28
DE60031422D1 (de) 2006-11-30
EP1212352A1 (en) 2002-06-12
AU7882200A (en) 2001-03-13
EP1212352A4 (en) 2002-12-04
EP1212352B1 (en) 2006-10-18
US6544750B1 (en) 2003-04-08
CA2382056A1 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
DE69532754T2 (de) Faktor xa inhibitoren
DE69427370T2 (de) Neue integrinbindende peptide
US10376557B2 (en) Peptide fragments for inducing synthesis of extracellular matrix proteins
Berndt et al. Identification of aspartic acid 514 through glutamic acid 542 as a glycoprotein Ib-IX complex receptor recognition sequence in von Willebrand factor. Mechanism of modulation of von Willebrand factor by ristocetin and botrocetin
DE60031422T2 (de) Peptidanaloga als selektive Inhibitoren der Thrombinaktivierung des proteaseaktivierten Rezeptors 1
Vanderhaeghen et al. Proenkephalin,[Met] enkephalin, and oxytocin immunoreactivities are colocalized in bovine hypothalamic magnocellular neurons.
DE3586616T2 (de) Verfahren zur verhuetung und induktion menschlicher plaettchen-aggregation.
DE69212914T2 (de) Schnellsynthese und Screening von Peptidmimetika
DE60133271T2 (de) Behandlung von knorpelerkrankungen
DE69615339T2 (de) Verfahren zum nachweis des endogenen thrombin-potentials und thrombin substrate zur verwendung in diesen verfahren
DE3877765T2 (de) Polypeptide mit einer laminin-wirksamkeit.
DE69627191T2 (de) Bradikininanaloge als selektive thrombininhibitoren
Lawrence et al. Induction of histamine release from human skin mast cells by bradykinin analogs
AT404357B (de) Prothrombin-derivate
DE69424657T2 (de) Osteogene wachstums-oligopeptide und diese enthaltende pharmazeutische zusammensetzungen
DE69413817T2 (de) Faktor vii-peptide
DE69425745T2 (de) Verfahren und zusammensetzungen zur behandlung der thrombose
DE60014919T2 (de) Peptidantagonisten des faktors viia
DE69931140T2 (de) Hemmung der angiogenese durch peptidanaloge der kininogen domäne 5mit hohem molekulargewicht
US7074765B2 (en) Synthetic peptide analogs of Arg-Pro-Pro-Gly-Phe as selective inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4
DE60033783T2 (de) Regulatorische/entfaltende peptide von ezrin
DE3014582A1 (de) Synthetisches antigenaktives polypeptid, verfahren zu dessen herstellung, das polypeptid enthaltendes antigenes mittel oder arzneimittel und deren verwendung
DE69420574T2 (de) Derivate von therapeutisch in der blutgerinnungskaskade wirksamen peptiden, verfahren zur herstellung und sie enthaltende pharmazeutische zubereitungen
DE69010750T2 (de) Antikörper gegen Fibrin, immunogene Peptide für die Herstellung dieser Antikörper, Verfahren zur Bestimmung von Fibrin und pharmazeutische Zubereitungen auf der Basis dieser Antikörper.
EP1096951B1 (de) Verwendung von bromelainproteasen zur hemmung der blutgerinnung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee